BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in immunology, 2011 - cell.com
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in Immunology, 2011 - cell.com
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in Immunology, 2011 - infona.pl
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
[HTML][HTML] BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in immunology, 2011 - ncbi.nlm.nih.gov
BAFF is a critical survival factor for transitional and mature B cells and is a promising
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …
BAFF and selection of autoreactive B cells.
Z Liu, A Davidson - Trends in Immunology, 2011 - europepmc.org
BAFF is a critical survival factor for transitional and mature B cells and is a promising
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …
BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in immunology, 2011 - pubmed.ncbi.nlm.nih.gov
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in Immunology, 2011 - Elsevier
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
[引用][C] BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in Immunology, 2011 - cir.nii.ac.jp
BAFF and selection of autoreactive B cells | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …
BAFF and selection of autoreactive B cells
Z Liu, A Davidson - Trends in immunology, 2011 - dialnet.unirioja.es
B cell activating factor (BAFF) is a crucial survival factor for transitional and mature B cells,
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
and is a promising therapeutic target for systemic lupus erythematosus (SLE). A BAFF …
BAFF and selection of autoreactive B cells.
Z Liu, A Davidson - Trends in Immunology, 2011 - europepmc.org
BAFF is a critical survival factor for transitional and mature B cells and is a promising
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …
therapeutic target for SLE. A BAFF inhibitor, belimumab, is the first new drug in 50 years to …